...
首页> 外文期刊>International Journal of Environmental Research and Public Health >Study of the In Vitro Antagonistic Activity of Various Single-Strain and Multi-Strain Probiotics against Escherichia coli
【24h】

Study of the In Vitro Antagonistic Activity of Various Single-Strain and Multi-Strain Probiotics against Escherichia coli

机译:各种单菌株和多菌株益生菌对大肠杆菌的体外拮抗活性研究

获取原文

摘要

Escherichia coli is an important commensal of our gut, however, many pathogenic strains exist, causing various severe infections in the gut or beyond. Due to several antibiotic resistance patterns of E. coli , research of alternative treatments or adjuvant therapy is important. One of these is the use of probiotics as antagonistic agents against E. coli . Most published studies investigate only one strain of E. coli and single-strain probiotics. The objectives of this study were to evaluate the antagonistic activity of selected single-strain and multi-strain probiotic supplements against selected clinical E. coli pathotypes using the in vitro agar spot test and the co-culturing method. Molecular methods were used to determine the presence of the genus lactobacilli and bifidobacteria as well as certain selected strains in the probiotic supplements. The agar-spot test showed that the multi-strain probiotics were more effective than the single-strain probiotics. On the other hand, the co-culturing method showed the opposite result, indicating that results are importantly influenced by the chosen method. The most effective single-strain probiotics against E. coli strains were Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus reuteri DSM 17938. The most effective multi-strain probiotics contained lactobacilli, bifidobacteria and enterococci strains, thus proving that most effective probiotics against E. coli strains are the lactic acid bacteria and bifidobacteria. The overall results from both in vitro tests reveal that all selected probiotics exhibited an antagonistic activity against all E. coli strains. From a public health perspective probiotics have thus proved to be successful in inhibiting the growth of E. coli and could therefore be used as adjuvant therapy or alternative therapy in E. coli infections.
机译:大肠杆菌是肠道的重要标志,但是,存在许多致病菌,会在肠道内外造成各种严重的感染。由于大肠杆菌的几种抗生素耐药性模式,替代疗法或辅助疗法的研究非常重要。其中之一是益生菌作为抗大肠杆菌的拮抗剂的用途。大多数发表的研究仅调查一种大肠杆菌和单菌株益生菌。这项研究的目的是使用体外琼脂斑点试验和共培养方法,评估选定的单菌株和多菌株益生菌补充剂对所选临床大肠杆菌病原菌的拮抗活性。分子方法用于确定益生菌补充剂中乳酸杆菌属和双歧杆菌属以及某些选定菌株的存在。琼脂斑点试验表明,多菌株益生菌比单菌株益生菌更有效。另一方面,共培养方法显示相反的结果,表明结果受所选方法的重要影响。针对大肠杆菌菌株最有效的单菌株益生菌是动物双歧杆菌亚种。乳酸菌BB-12和罗伊氏乳杆菌DSM17938。最有效的多菌株益生菌包含乳酸菌,双歧杆菌和肠球菌菌株,因此证明对大肠杆菌菌株最有效的益生菌是乳酸菌和双歧杆菌。两项体外试验的总体结果表明,所有选定的益生菌均表现出对所有大肠杆菌菌株的拮抗活性。因此,从公共卫生的角度来看,益生菌已被证明可以成功地抑制大肠杆菌的生长,因此可以用作大肠杆菌感染的辅助疗法或替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号